Posted by Michael Wonder on 28 Oct 2022
European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV prevention
28 October 2022 - The marketing application is based on results from the HPTN 083 and 084 Phase 2b/3 studies in which the injectable medicine, given as few as six times per year, demonstrated superior efficacy to a daily oral PrEP option in reducing the risk of HIV acquisition.
ViiV Healthcare today announced that the EMA has validated the company’s marketing authorisation application seeking approval of cabotegravir long-acting injectable for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1.
